Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500422 · ClinicalTrials.gov registry record · Phase 1
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
NCT00500422: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00500422 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 134 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (123% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00500422, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest safe dose of the drug Velcade (bortezomib) that can be given together with gemcitabine and pegylated liposomal doxorubicin (Doxil) in the treatment of advanced cancer. The effect of this combination treatment on tumor growth will also be studied.
Interventions
- DRUG Gemcitabine
- DRUG Doxil
- DRUG Velcade
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2005-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
What the finished NCT00500422 record still lists
NCT00500422 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (123% higher).
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT00500422 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00500422 about?
NCT00500422 is a clinical study titled "Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients". The goal of this clinical research study is to find the highest safe dose of the drug Velcade (bortezomib) that can be given together with gemcitabine and pegylated liposomal doxorubicin (Doxil) in the treatment of advanced cancer. The effect of this combination treatment on tumor growth will also b...
What is the current status of trial NCT00500422?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2005-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00500422?
The interventions under investigation include: Gemcitabine (DRUG), Doxil (DRUG), Velcade (DRUG).
Who is sponsoring clinical trial NCT00500422?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00500422's enrollment target sits among peer trials
134 427th of 2000 higher than 1,569 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia